Biotech Values

[oc631]

Does such SCR36 data exist for GS-7977 without Ifn?

To my knowledge there have been no relapsers beyond four weeks post-therapy in any subgroup including nulls. The next couple of weeks are critical for GILD investors because relapse further into the follow-up period would not be overlooked by the market. One or two relapsers would induce investor anxiety up until the completion of follow-up period for all patients. If this happens it should only be short-term negative considering GILD has a pipeline of DAA candidates to test with GS-7977.

With this drug I can't imagine relapse beyond the 12-week follow-up period. Hold me to it. Stranger things have happened.